SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending following the expansion of its partnership with Google Cloud, allowing customers to integrate Gemini AI models directly into their Oracle database infrastructure. Community sentiment remains split between excitement over this long-term AI enterprise strategy and skepticism regarding the company's significant debt load and capital expenditures.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as retail investors rally behind a potential short squeeze, fueled by record short interest, shrinking share availability, and elevated borrow fees. Community excitement is further amplified by the upcoming Northern Data acquisition and strategic partnerships with Tether, which investors believe position the company as an emerging player in the AI cloud infrastructure space.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify (SPOT) is facing significant volatility and investor scrutiny as the market weighs high-profile analyst upgrades against earnings-related jitters and concerns over slowing user growth. Community discussion is sharply divided, with many traders debating whether recent price hikes and AI-driven features will successfully drive margin expansion or if the stock remains overvalued and vulnerable to broader tech sector rotation.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. It operates through the following segments: Seed and Integrated Products, Crop Protection, Crop Nutrition, and Emerging Solutions. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science is currently a focal point for day traders and momentum-focused investors, with community discussions largely centered on its low-float status and high volatility potential. Many traders are actively debating whether the stock is primed for a significant breakout or is merely a target for coordinated pump-and-dump activity, while others are closely monitoring technical indicators and order flow for potential squeeze setups.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending after reporting its first revenue growth in nearly five years, with the company focusing on a reset operating strategy and cost-cutting initiatives. Community members are actively debating the viability of this turnaround story, with some traders analyzing recent volume and technical patterns while others remain skeptical of the company's long-term sustainability.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as it breaks into new all-time highs, fueled by intense institutional accumulation and relentless demand for AI infrastructure. The community is actively debating the stock's massive market cap expansion and the validity of AI-driven hyperscaler spending, with many interpreting the current momentum as a sign of continued secular growth.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is generating significant discussion as investors weigh the company's aggressive restructuring, including widespread job cuts and Amazon volume reductions, against its upcoming earnings and potential for margin recovery. The community is actively debating the stock's turnaround potential, focusing on dividend stability, leadership strategy, and the impact of broader transportation sector volatility.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining momentum as a community-driven project, with supporters actively coordinating buys, holding through market volatility, and pushing for growth milestones. The community is heavily focused on the developer's engagement, including planned airdrops and website updates, as they look to capitalize on the project's low market cap and potential for a breakout.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending as the community rallies around hopes for a potential supply-side recovery and sustained interest in token burns. Traders are actively discussing the impact of future ecosystem developments and the ongoing influence of major holdings on long-term price action.

Greenland Energy Co. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2024 and is headquartered in New York, NY.

Greenland Energy Co.

Greenland Energy Co. is experiencing intense volatility as investors react to a significant secondary offering filing, with the community sharply divided between those viewing the stock as a speculative energy play with long-term drilling potential and those dismissing it as a pump-and-dump scheme. Active discussion is currently centered on the stock's massive short interest, rising cost-to-borrow fees, and the impact of upcoming dilution on the share price as traders speculate on potential short squeezes versus further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lifesci Capital Has Pessimistic Outlook of RCKT Q1 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Lifesci Capital cut their Q1 2026 EPS estimates for shares of Rocket Pharmaceuticals in a research report issued on Thursday, April 16th...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by Brokerages

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) has received a consensus rating of "Hold" from the eighteen ratings firms that are presently covering the stock, Marketbeat Ratings...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Short Interest Update

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totaling 18,580,923 shares, an increase of 26.5% from the March 15th total of 14,693,507 shares. Currently, 22.6% of the company's...

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Pass Below 50-Day Moving Average   - Here's What Happened

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Passes Below 50-Day Moving Average - Here's What Happened...

Rocket Pharmaceuticals, Inc. $RCKT Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 73.6% during the third quarter, according to its most recent disclosure with the SEC...

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.

Bank of America Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Bank of America upped their target price on shares of Rocket Pharmaceuticals from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Monday...

<ul class="summary-bullets"><li>The company also said that the FDA granted the company a Rare Pediatric Disease Priority Review Voucher (PRV) following the approval.</li><li>Wedbush reiterated an ‘Outperform’ rating and $16 price target on Rocket Pharmaceuticals, saying the Kresladi approval is a "significant milestone" for the company.</li><li>LifeSci Capital added that it is impressive Rocket was able to usher Kresladi through a complex cell-based gene therapy approval.</li></ul>&nbsp;Shares of Rocket Pharmaceuticals Inc. (RCKT) dropped 22% on Friday after the company announced U.S. Food and Drug Administration's approval for its drug in the treatment of an inherited pediatric disorder, a sell-off that Wall Street dismissed as unjustified.Earlier on Friday, Rocket announced that the FDA has approved its gene therapy Kresladi for the treatment of certain pediatric patients with severe leukocyte adhesion deficiency-I, an ultra-rare, inherited pediatric immunodeficiency characterized by recurrent, severe infections.The company also said that the FDA granted the company a Rare Pediatric Disease Priority Review Voucher (PRV) following the approval. The voucher is designed to encourage the development of therapies for rare pediatric disease<h2 class="st-heading-2">Wall Street Weighs In</h2>Wedbush reiterated an ‘Outperform’ rating and $16 price target on Rocket Pharmaceuticals, saying the Kresladi approval is a "significant milestone" for the company, which the firm believes reflects management's strong execution. Payer coverage should not be an issue, and the priority review voucher will strengthen Rocket's balance sheet, the analyst told investors in a research note. The firm added that it does not see the negative stock price reaction as justified.LifeSci Capital analyst Patrick Dolezal also reiterated an ‘Outperform’ rating and $9 price target on Rocket Pharmaceuticals. The firm said the PRV could be a potentially meaningful source of non-dilutive capital that could net Rocket $100 million to $200 million. The firm added that it is impressive Rocket was able to usher Kresladi through a complex cell-based gene therapy approval and expects read-through to the company's cardiac gene-therapy pipeline.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around RCKT stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/RCKT">RCKT stock</a> has fallen 53% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-model-y-3-deliveries-critical-as-model-s-x-approach-retirement-says-analyst/cZ3HJsGRIm9">Watch Tesla Model Y/3 Q1 Delivery Numbers Closely — Analyst Warns As S/X Near End Of Production</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off

Earlier on Friday, Rocket announced that the FDA has approved its gene therapy Kresladi for the treatment of certain pediatric patients with an ultra-rare immune disorder.

Equity

Earlier on Friday, Rocket announced that the FDA has approved its gene therapy Kresladi for the treatment of certain pediatric patients with an ultra-rare immune disorder.


Chardan Capital Reiterates Buy Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

Chardan Capital restated a "buy" rating and issued a $11.00 target price on shares of Rocket Pharmaceuticals in a research note on Friday...

Promising Biotech Stocks To Add to Your Watchlist - March 27th

Danaher, Onconetix, Moderna, argenex, Vertex Pharmaceuticals, Abivax, and Rocket Pharmaceuticals are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Current Price	$3.49
Prev Close	$3.52
Open	$3.53
Dividend Yield	0.00%
50-Day Moving Average	$4.11
Beta	1.17
Avg. Volume	5.11M
PE Ratio	-1.74

52-Week High	$8.26
52-Week Low	$2.19
Market Capitalization	$384.11M
EPS (Annual)	-$2.01
Price to Book	1.36
Revenue Per Employee	$0.00

RCKT
Rocket Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RCKT News

RCKTRocket Pharmaceuticals Inc